HER2-Negative Breast Cancer Completed Phase 1 Trials for RG-4733 (DB11870)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01158274RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsTreatment